D-0647-2020 Class II Terminated
FDA drug recall D-0647-2020 was initiated by Akorn, Inc. on Nov 15, 2019 and is designated Class II. Reason for recall: Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count… The recall status is terminated (terminated Aug 9, 2022). Affected quantity: 4,206 boxes.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 8, 2020
- Initiation Date
- Nov 15, 2019
- Termination Date
- Aug 9, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 4,206 boxes
Product description
MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by: VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.
Reason for recall
Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.
Distribution pattern
Nationwide in the USA and Puerto Rico
Code information
Lot V20M54A, Exp 01/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0647-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026